Back to results

Cannabis For Cancer-Related Symptoms (CAFCARS)

Primary Purpose

Pain, Nausea, Anxiety

Status

Recruiting

Phase

Phase 2

Locations

Canada

Study Type

Interventional

Intervention

Cannabis

About this trial

This is an interventional treatment trial for Pain

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

At least 19 years of age;
Competent to consent to participation in the study;
Must have at least one of the following cancer-related symptoms or a cancer treatment-related symptoms which is causing distress: Nausea; Pain; Anxiety; Sleep Disturbance; (based on ESAS-r-SN score ≥4/10)
Symptom(s) are expected to be stable throughout the duration of the study;
Expecting to live for at least 4 months;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2;
Willing to commit to not taking cannabis in any form other than the study products for the duration of the study;
Able to reliably communicate with the research team, either directly or through a translator;
Accessible by telephone.

Exclusion Criteria:

Their current symptoms are not related to cancer or cancer treatment;
They have a current cannabis or other substance dependence or misuse disorder as defined by the revised Cannabis Use Disorder Identification Test (CUDIT-R) score of 8 or above;
They admit to cannabis use for any purpose (recreational or medicinal) more than once a week during the month prior to study entry;
They have a history of psychosis with, or other intolerance to cannabis or cannabinoids;
They have an active psychiatric disorder likely, in the investigator's opinion, to interfere with adherence to study protocol;
They have any concurrent condition likely to interfere with completion of the study protocol, such as allergy to any component of the study products;
They are pregnant or planning to get pregnant or they are lactating females;
They are women of childbearing potential (<2 years after last menstruation) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal);
They have reproductive potential and fail to use adequate birth control;
They are on another clinical trial or expect to start one prior to study completion;
They have oral disease which might impair trans-mucosal absorption, e.g. oral mucositis;
They are taking medications that might be affected by an interaction with cannabinoids in a clinically significant manner (CYP1A1, 1A2, and 1B1) and cannot be switched to a different medication;
They live in an environment with high risk of theft or diversion of study products;
They have a concurrent condition that requires changes to current medications within the 48 days on study treatment.
They have serious cardiovascular disease such as ischemic heart disease, including arrhythmias, poorly controlled hypertension, severe heart failure, recent (within 6 months) MI.
They have first degree relatives with schizophrenia.
They have history of epilepsy or repeated seizures or brain metastases.
They are unable or unwilling to refrain from driving a vehicle or operating heavy machinery for the duration of their participation in this study.
They are unable or unwilling to refrain from consuming alcohol for the duration of their participation in this study.
They expect to leave Canada during the study period, as the study products cannot be taken across any international border (land, sea or air).

Sites / Locations

Tom Baker Cancer CentreRecruiting
BC Cancer Center of the NorthRecruiting
BC Cancer VancouverRecruiting
BC Cancer - VictoriaRecruiting
CancerCare ManitobaRecruiting
Kingston Health Sciences Centre - Kingston General Hospital SiteRecruiting
Ottawa Hospital Cancer CentreRecruiting
Santé CannabisRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Arm Label

High THC/Low CBD Cannabis Oil

Low THC/High CBD Cannabis Oil

Equal amounts of THC/CBD Cannabis Oil

Placebo Oil

Arm Description

THC+THCa = 573 mg CBD+CBDA = 0 mg Total cannabinoids = 573 mg (0.95mg/drop) Dried marijuana equivalent = 5g

THC+THCa = 37mg CBD+CBDA = 784mg Total cannabinoids = 821mg (1.37mg/drop) Dried marijuana equivalent = 6g

THC+THCa = 516mg CBD+CBDA = 456mg Total cannabinoids = 972mg (1.62mg/drop) Dried marijuana equivalent = 6g

Medium Chain Triglyceride (MCT) oil

Outcomes

Primary Outcome Measures

Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms

The PGIC provides a single, general estimate of improvement or deterioration using scores from 1 to 7 and has been used as a research outcome indicator in a variety of contexts, particularly in chronic pain. The PGIC asks subjects to rate their current status as: No change (or condition worse) Almost the same (hardly any change at all) A little better (no noticeable change) Somewhat better (change has not made any real difference Moderately better (slight but noticeable change) Better (definite improvement that has made a real and worthwhile difference) A great deal better and a considerable improvement that has made all the difference Subjects will be reporting their PGIC score 90 minutes after each dose of cannabis oil (1 to 6 times daily). Only scores collected on non-washout days of a treatment cycle corresponding to a particular oil formulation will be used.

Secondary Outcome Measures

Average change from baseline in the Edmonton Symptom Assessment System - revised to include Sleep Disturbance and Night Sweats (ESAS-r-SN) score

The ESAS-r-SN is a set of 0-10 numerical scales that patients use to rate the severity of the most common cancer-related symptoms. A score of 0 means that patients are not experiencing that symtpom and a score of 10 indicates that patients are experiencing the most severe symptom (for example, experiencing a pain score of 10 indicates worst possible pain). Subjects will be reporting their ESAS-r-SN scores once daily. Only scores collected on non-washout days of a treatment cycle corresponding to a particular oil formulation will be used.

Full Information

NCT ID

NCT03948074

First Posted

May 9, 2019

Last Updated

July 18, 2023

Sponsor

Pippa Hawley

1. Study Identification

Unique Protocol Identification Number

NCT03948074

Brief Title

Cannabis For Cancer-Related Symptoms

Acronym

CAFCARS

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multiple Crossover N-of-1 Study Design of the Use of Medicinal Cannabis Oil-Based Extracts for Symptom Management in Cancer Patients

Study Type

Interventional

2. Study Status

Record Verification Date

July 2023

Overall Recruitment Status

Recruiting

Study Start Date

February 1, 2021 (Actual)

Primary Completion Date

March 1, 2024 (Anticipated)

Study Completion Date

March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Pippa Hawley

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each patient relative to placebo. Investigators propose a randomized, double-blind, N-of-1 trial to test the effectiveness of each cannabis extract combination using cannabis oils in a minimum of 120 patients on 4 cancer-related symptoms: nausea, pain, anxiety and sleep disturbance. The three active treatments will be the following cannabis oil extract combinations: High THC/Low CBD, Low THC/High CBD, and Equal amounts of THC/CBD. THC = Tetrahydrocannabinol CBD = Cannabidiol The placebo treatment will be Medium Chain Triglyceride (MCT) oil. The active oils and the placebo are similar in taste, smell and effectively blind subjects. Primary objective: To identify whether there is an active cannabis extract that is more effective than placebo in managing overall cancer-related symptoms for individual subjects who completed at least 1 treatment cycle for the entire patient population represented by those individual subjects, and for subsets of that subject population defined by relevant baseline patient characteristics. Secondary objective: To identify whether there is a cannabis extract that is more effective than placebo in managing each of the 4 index symptoms (pain, nausea, anxiety and sleep disturbance) for individual subjects who completed at least 1 treatment cycle, for the entire patient population represented by those individual subjects, and for subsets of that subject population defined by relevant baseline patient characteristics. Tertiary objectives: To investigate the safety (e.g., serious adverse events) of each of the three cannabis extracts. To identify subject preference of each of the 4 oils (if any).

Detailed Description

Investigators propose a study consisting of a series of N-of-1 trials comparing 3 different active cancer-related symptom management treatments against a placebo treatment in terms of effectiveness and safety. Using formal statistical modeling, effectiveness will be assessed for single patients, for the entire patient population and for relevant subsets of the patient population defined by baseline patient characteristics. Safety will be assessed in a descriptive fashion for all patients who are part of the safety population. Subjects will be on treatment in the study for a minimum of 16 days with the opportunity to repeat the 16-day cycle of cancer-related symptom treatment with all four oil extracts up to 2 more times. The extracts will be supplied to subjects at the beginning of the study in four distinct 30-ml bottles, randomly labelled as #1, #2, # 3 and # 4. The random labelling will be generated via a computer-generated randomization code. The study will include at least 120 adult subjects (recruitment target 150 to allow for drop-outs) residing in Canada who have symptoms from cancer and/or from cancer treatment but will exclude patients with active recreational use, cannabis use disorder, or high risk of diversion. Each treatment cycle will have a length of 16 days and will consist of 4 four-day periods. The first 2 days of each 4-day period will be a washout period where data will not be used for the analysis of effectiveness, to make sure there is no confusion with effects from the prior period. Subjects can use one and only one cannabis oil extract during each period to treat their cancer-related symptom(s). Given a cannabis oil extract, the daily use of that extract by patients will involve the following: On each day within a specific treatment cycle, the patient will be asked to take a minimum of 3 drops of that extract per day (e.g., in the morning) and if any of the four major symptoms (nausea, pain, anxiety, and sleep disturbance) continue to trouble the patient as the day progresses, they will be instructed to take up to 3 drops every 4 hours for a maximum of 6 times a day (for a total of no more than 18 drops per day). All subjects will be instructed to use the following validated scales: Edmonton Symptom Assessment Scale (ESAS) and Patients' Global Impression of Change Scale (PGIC). The revised ESAS will be used modified to include sleep disturbance (previously validated), and added night sweats in replacement of the additional symptom option (ESAS-r-SN) because of reports of benefit of medical cannabis for this symptom and its relevance for sleep disturbance.This is in order to capture a complete picture of potential factors contributing to sleep disturbance. Additionally, subjects will be instructed to fill in a study medication use log which will record the timing and dose of each extract applications, any side effects associated with each application, as well as any rescue medication (if taken).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pain, Nausea, Anxiety, Sleep Disturbance

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Crossover Assignment

Model Description

An N-of-1 trial is a crossover trial, usually randomized and often blinded, conducted in a single patient. This type of trial provides an objective, data-driven way to determine the most effective intervention for an individual patient from among a set of competing interventions and to investigate the side-effect profiles of each intervention. It is possible to analyze the results produced by each N-of-1 trial in a series separately in order to determine whether (i) the active treatment(s) involved in the trial were effective for the corresponding patient or (ii) the novel treatment(s) involved in the trial were effective relative to the established treatment. It is also possible to aggregate the results produced by a series of simultaneous N-of-1 trials (all conducted in a similar way) using either meta-analytic methods or mixed effects modelling in order to obtain information on how to treat subsets of the target patient population or even the entire patient population at large.

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

High THC/Low CBD Cannabis Oil

Arm Type

Experimental

Arm Description

THC+THCa = 573 mg CBD+CBDA = 0 mg Total cannabinoids = 573 mg (0.95mg/drop) Dried marijuana equivalent = 5g

Arm Title

Low THC/High CBD Cannabis Oil

Arm Type

Experimental

Arm Description

THC+THCa = 37mg CBD+CBDA = 784mg Total cannabinoids = 821mg (1.37mg/drop) Dried marijuana equivalent = 6g

Arm Title

Equal amounts of THC/CBD Cannabis Oil

Arm Type

Experimental

Arm Description

THC+THCa = 516mg CBD+CBDA = 456mg Total cannabinoids = 972mg (1.62mg/drop) Dried marijuana equivalent = 6g

Arm Title

Placebo Oil

Arm Type

Placebo Comparator

Arm Description

Medium Chain Triglyceride (MCT) oil

Intervention Type

Drug

Intervention Name(s)

Cannabis

Other Intervention Name(s)

Tetrahydrocannabinol, Cannabidiol

Intervention Description

Medicinal Cannabis Oil

Primary Outcome Measure Information:

Title

Average Patients' Global Impression of Change (PGIC) for overall cancer-related symptoms

Description

Time Frame

16-48 days; 90 minutes after each dose

Secondary Outcome Measure Information:

Title

Average change from baseline in the Edmonton Symptom Assessment System - revised to include Sleep Disturbance and Night Sweats (ESAS-r-SN) score

Description

Time Frame

16-48 days; once daily

Other Pre-specified Outcome Measures:

Title

Percent of subjects who prefer each study oil (Oil 1, 2, 3 or 4)

Description

Subjects will be asked by study personnel at the end of the study which oil they preferred most (i.e. Oil 1, 2, 3, or 4) after study completion but prior to un-blinding and preference of oils will be recorded. Percentages of subjects who prefer each type of oil will be recorded.

Time Frame

16-48 days

10. Eligibility

Sex

All

Minimum Age & Unit of Time

19 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: At least 19 years of age; Competent to consent to participation in the study; Must have at least one of the following cancer-related symptoms or a cancer treatment-related symptoms which is causing distress: Nausea; Pain; Anxiety; Sleep Disturbance; (based on ESAS-r-SN score ≥4/10) Symptom(s) are expected to be stable throughout the duration of the study; Expecting to live for at least 4 months; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; Willing to commit to not taking cannabis in any form other than the study products for the duration of the study; Able to reliably communicate with the research team, either directly or through a translator; Accessible by telephone. Exclusion Criteria: Their current symptoms are not related to cancer or cancer treatment; They have a current cannabis or other substance dependence or misuse disorder as defined by the revised Cannabis Use Disorder Identification Test (CUDIT-R) score of 8 or above; They admit to cannabis use for any purpose (recreational or medicinal) more than once a week during the month prior to study entry; They have a history of psychosis with, or other intolerance to cannabis or cannabinoids; They have an active psychiatric disorder likely, in the investigator's opinion, to interfere with adherence to study protocol; They have any concurrent condition likely to interfere with completion of the study protocol, such as allergy to any component of the study products; They are pregnant or planning to get pregnant or they are lactating females; They are women of childbearing potential (<2 years after last menstruation) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal); They have reproductive potential and fail to use adequate birth control; They are on another clinical trial or expect to start one prior to study completion; They have oral disease which might impair trans-mucosal absorption, e.g. oral mucositis; They are taking medications that might be affected by an interaction with cannabinoids in a clinically significant manner (CYP1A1, 1A2, and 1B1) and cannot be switched to a different medication; They live in an environment with high risk of theft or diversion of study products; They have a concurrent condition that requires changes to current medications within the 48 days on study treatment. They have serious cardiovascular disease such as ischemic heart disease, including arrhythmias, poorly controlled hypertension, severe heart failure, recent (within 6 months) MI. They have first degree relatives with schizophrenia. They have history of epilepsy or repeated seizures or brain metastases. They are unable or unwilling to refrain from operating heavy machinery for the duration of their participation in this study. They are unable or unwilling to refrain from consuming alcohol for the duration of their participation in this study. They expect to leave Canada during the study period, as the study products cannot be taken across any international border (land, sea or air).

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Alshanee Sharma

Phone

604-877-6000

Ext

674417

alshanee.sharma@bccancer.bc.ca

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Philippa Hawley, FRCPC

Organizational Affiliation

BC Cancer

Official's Role

Principal Investigator

Facility Information:

Facility Name

Tom Baker Cancer Centre

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4N2

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Luke Goudie

Phone

403-521-3925

luke.goudie@albertahealthservices.ca

First Name & Middle Initial & Last Name & Degree

Marc Kerba

Facility Name

BC Cancer Center of the North

City

Prince George

State/Province

British Columbia

ZIP/Postal Code

V2M 7E9

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sarah Zuccaro

Phone

250-645-7300

Ext

687428

sarah.zuccaro@bccancer.bc.ca

First Name & Middle Initial & Last Name & Degree

Robert Olson

Facility Name

BC Cancer Vancouver

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 4E6

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alshanee Sharma

Phone

604-877-6000

Ext

674417

alshanee.sharma@bccancer.bc.ca

First Name & Middle Initial & Last Name & Degree

Philippa Hawley, FRCPC

Facility Name

BC Cancer - Victoria

City

Victoria

State/Province

British Columbia

ZIP/Postal Code

V8R 6V5

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Saboura Mahdavi

Phone

250-519-5500

Ext

695423

saboura.mahdavi@bccancer.bc.ca

First Name & Middle Initial & Last Name & Degree

Kevin Wade

Facility Name

CancerCare Manitoba

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R3E 0V9

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Kyle Wojcik

Phone

204-237-2128

kwojcik@cancercare.mb.ca

First Name & Middle Initial & Last Name & Degree

Paul Daeninck

Facility Name

Kingston Health Sciences Centre - Kingston General Hospital Site

City

Kingston

State/Province

Ontario

ZIP/Postal Code

K7L 2V7

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Noureen Hassan

Phone

613-549-6666

Ext

7432

noureen.hassan@kingstonhsc.ca

First Name & Middle Initial & Last Name & Degree

Craig Goldie

Facility Name

Ottawa Hospital Cancer Centre

City

Ottawa

State/Province

Ontario

ZIP/Postal Code

K1H 8L6

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Stephanie Downar

Phone

416-908-9504

sdownar@ohri.ca

First Name & Middle Initial & Last Name & Degree

Edward Fitzgibbon

Facility Name

Santé Cannabis

City

Montréal

State/Province

Quebec

ZIP/Postal Code

H3Z 2Y5

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Natalia Cherba

Phone

514-419-4131

Ext

121

natalia@santecannabis.ca

First Name & Middle Initial & Last Name & Degree

Michael Dworkind

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Cannabis For Cancer-Related Symptoms

We'll reach out to this number within 24 hrs